Business

Senores Pharmaceuticals Acquires 14 ANDAs from Dr Reddy's to Expand Presence in US Market

While the financial terms of the transaction remain undisclosed, the deal includes a portfolio of 13 ANDAs that have already secured approval from the US Food and Drug Administration (USFDA), with one additional application currently awaiting regulatory clearance.

• By Newsdesk
• Gujarat
• Mar 04, 2025

Business

Gujarat-based drug manufacturer Senores Pharmaceuticals has announced the acquisition of 14 Abbreviated New Drug Applications (ANDAs) from Dr Reddy's Laboratories, marking a significant step in its expansion strategy for the US pharmaceutical market.

In a statement released on Tuesday, Senores Pharmaceuticals, Inc., USA—a wholly owned subsidiary of the Indian pharmaceutical firm—confirmed the agreement with Dr Reddy's for the acquisition. While the financial terms of the transaction remain undisclosed, the deal includes a portfolio of 13 ANDAs that have already secured approval from the US Food and Drug Administration (USFDA), with one additional application currently awaiting regulatory clearance.

The acquired ANDAs represent a lucrative opportunity in the US market, with an estimated valuation of approximately USD 421 million, based on data from global healthcare analytics firm IQVIA. The acquisition is set to be funded through the proceeds of Senores Pharmaceuticals’ recent Initial Public Offering (IPO), aligning with the objectives outlined in the company’s Red Herring Prospectus.

Swapnil Shah, Managing Director of Senores Pharmaceuticals, emphasized the strategic importance of the acquisition, highlighting that the molecules included in the portfolio span multiple therapeutic categories with rising demand. According to Shah, the portfolio comprises both controlled substances and general category products, allowing for broad market penetration across diverse distribution channels, including government institutions, retail pharmacies, and specialty clinics.

"This acquisition significantly strengthens our product portfolio in the US market while also enhancing our presence in other regulated and semi-regulated global markets," Shah noted. The move underscores Senores Pharmaceuticals’ commitment to expanding its footprint in international markets and capitalizing on the growing demand for high-quality, affordable generics.

The acquisition reflects the company’s long-term vision of bolstering its global pharmaceutical footprint, leveraging its newly acquired ANDAs to drive growth and enhance accessibility to essential medications in key markets.

(With inputs from PTI)